Shortlist

EV/EBIT of 6.8 against a Healthcare median of 20.8 — 67% below peers. Free cash flow yield 14.7%. Trading 74% below its all-time high set 2000-08-25.

At the Healthcare median EV/EBIT of 20.8 instead of its current 6.8, and with earnings unchanged, the equity would be worth about 221% more. That is the size of the gap, not a forecast that it closes.

• ROIC 760% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 48% over three years
• net debt 0.5x EBITDA — balance sheet not forcing anything

Consensus strong buy from 11 analysts, mean target 20.82 USD, 143% above the current price. No revision activity in the last quarter.

Targets spread 96% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Implied upside of 143% is unusually high. The evidence runs the other way here: stocks with the most optimistic targets tend to underperform, because the optimism bias is real and priced-in slowly. Read this as a caution, not an opportunity.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 11.1 against a Consumer Cyclical median of 17.6 — 37% below peers. Free cash flow yield 9.8%. Trading 45% below its all-time high set 2018-09-27.

At the Consumer Cyclical median EV/EBIT of 17.6 instead of its current 11.1, and with earnings unchanged, the equity would be worth about 58% more. That is the size of the gap, not a forecast that it closes.

• ROIC 51% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt 0.0x EBITDA — balance sheet not forcing anything
• Altman Z 9.4 — outside the distress zone

Consensus buy from 12 analysts, mean target 41.50 USD, 36% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 10.6 against a Technology median of 28.6 — 63% below peers. Free cash flow yield 10.3%. Trading 65% below its all-time high set 2021-11-19.

At the Technology median EV/EBIT of 28.6 instead of its current 10.6, and with earnings unchanged, the equity would be worth about 169% more. That is the size of the gap, not a forecast that it closes.

• ROIC 63% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 11% over three years
• net debt 0.0x EBITDA — balance sheet not forcing anything

Consensus hold from 34 analysts, mean target 270.61 USD, 12% above the current price. Revisions over the last quarter have been net negative — the sell side is marking this down.

Targets spread 70% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 25.4 against a Technology median of 28.6 — 11% below peers. Free cash flow yield 5.2%. Trading 37% below its all-time high set 2021-08-25.

At the Technology median EV/EBIT of 28.6 instead of its current 25.4, and with earnings unchanged, the equity would be worth about 13% more. That is the size of the gap, not a forecast that it closes.

• ROIC 40% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 13% over three years
• net debt 0.1x EBITDA — balance sheet not forcing anything

Consensus strong buy from 34 analysts, mean target 314.57 USD, 45% above the current price. No revision activity in the last quarter.

Targets spread 75% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 5.6 against a Consumer Defensive median of 16.2 — 66% below peers. Free cash flow yield 7.1%. Trading 47% below its all-time high set 2025-04-23.

At the Consumer Defensive median EV/EBIT of 16.2 instead of its current 5.6, and with earnings unchanged, the equity would be worth about 268% more. That is the size of the gap, not a forecast that it closes.

• ROIC 19% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• net debt 1.3x EBITDA — balance sheet not forcing anything
• Altman Z 3.4 — outside the distress zone

Consensus hold from 7 analysts, mean target 33.64 USD, 22% above the current price. No revision activity in the last quarter.

Targets spread 42% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 0.4 against a Technology median of 28.6 — 99% below peers. Free cash flow yield 201.0%. Trading 87% below its all-time high set 2000-03-03.

At the Technology median EV/EBITDA of 19.1 instead of its current 0.3, and with earnings unchanged, the equity would be worth about n/a more. That is the size of the gap, not a forecast that it closes.

• ROIC 33% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 8/9 — accounts improving year on year
• net debt -0.3x EBITDA — balance sheet not forcing anything
• operating margin 17%

mean target 9.67 SEK, 1% below the current price. No revision activity in the last quarter.

Targets spread 35% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Trading 1% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 14.1 against a Consumer Cyclical median of 17.6 — 20% below peers. Free cash flow yield 7.6%. Trading 32% below its all-time high set 2025-07-07.

At the Consumer Cyclical median EV/EBIT of 17.6 instead of its current 14.1, and with earnings unchanged, the equity would be worth about 25% more. That is the size of the gap, not a forecast that it closes.

• free cash flow positive
• revenue compounding at 16% over three years
• net debt 0.2x EBITDA — balance sheet not forcing anything
• Altman Z 6.1 — outside the distress zone
• operating margin 31%

Consensus buy from 36 analysts, mean target 237.81 USD, 53% above the current price. No revision activity in the last quarter.

Targets spread 48% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 4.6 against a Financial Services median of 8.5 — 46% below peers. Free cash flow yield 25.9%.

At the Financial Services median EV/EBIT of 8.5 instead of its current 4.6, and with earnings unchanged, the equity would be worth about 61% more. That is the size of the gap, not a forecast that it closes.

• ROIC 28% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 26% over three years
• operating margin 27%

Consensus buy from 19 analysts, mean target 111.87 USD, 18% above the current price. No revision activity in the last quarter.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 3.2 against a Financial Services median of 8.5 — 62% below peers. Free cash flow yield 33.2%. Trading 64% below its all-time high set 2025-06-09.

At the Financial Services median EV/EBIT of 8.5 instead of its current 3.2, and with earnings unchanged, the equity would be worth about 72% more. That is the size of the gap, not a forecast that it closes.

• ROIC 144% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 30% over three years
• net debt -4.0x EBITDA — balance sheet not forcing anything
• Altman Z 12.5 — outside the distress zone

Consensus buy from 14 analysts, mean target 48.43 USD, 78% above the current price. No revision activity in the last quarter.

Targets spread 118% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Implied upside of 78% is unusually high. The evidence runs the other way here: stocks with the most optimistic targets tend to underperform, because the optimism bias is real and priced-in slowly. Read this as a caution, not an opportunity.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

EV/EBIT of 6.6 against a Financial Services median of 8.5 — 22% below peers. Free cash flow yield 12.5%. Trading 83% below its all-time high set 2021-07-23.

At the Financial Services median EV/EBIT of 8.5 instead of its current 6.6, and with earnings unchanged, the equity would be worth about 28% more. That is the size of the gap, not a forecast that it closes.

• ROIC 28% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 9/9 — accounts improving year on year
• revenue compounding at 6% over three years
• net debt -0.1x EBITDA — balance sheet not forcing anything

Consensus hold from 33 analysts, mean target 59.77 USD, 14% above the current price. Revisions over the last quarter have been net positive, which is the part of analyst output the evidence actually supports.

Targets spread 186% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

P/E of 2.2 against a Communication Services median of 14.4 — 85% below peers.

No usable re-rating gap: the multiple is at or above its sector median, or the inputs were missing.

• ROIC 692% — still earning above a plausible cost of capital
• free cash flow positive
• Piotroski F-Score 7/9 — accounts improving year on year
• revenue compounding at 5% over three years
• net debt -4.1x EBITDA — balance sheet not forcing anything

Consensus strong buy from 32 analysts, mean target 161.33 CNY, 38% above the current price. No revision activity in the last quarter.

Targets spread 42% of the mean — analysts disagree sharply, and consensus loses its information content when they do.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.

Read off the statements over three years, not from any view about the company's prospects. What the numbers cannot tell you is whether management already has an answer.

EV/EBIT of 6.4 against a Financial Services median of 8.5 — 24% below peers. Free cash flow yield 14.3%.

At the Financial Services median EV/EBIT of 8.5 instead of its current 6.4, and with earnings unchanged, the equity would be worth about 28% more. That is the size of the gap, not a forecast that it closes.

• ROIC 54% — still earning above a plausible cost of capital
• free cash flow positive
• revenue compounding at 31% over three years
• operating margin 19%

mean target 150.00 ILS, 23% below the current price. Revisions over the last quarter are balanced.

Only 1 analyst estimate(s) — too few for a consensus to mean much.

Trading 23% above the consensus target — the sell side thinks it is expensive.

Price target levels are shown as context only and never feed the score. Targets are reached roughly half the time and the most optimistic ones tend to underperform. Revision direction is the part that carries information.